Clinical Trial Update: A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating venetoclax monotherapy in relapsed or refractory chronic lymphocytic leukemia; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Status: COMPLETED | Results posted: 2023-02-22